Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
CDZI$4.66-0.06(-1.17%)Cadiz Raises $21 Million in Registered Direct Offering Cadiz Inc. (NASDAQ: CDZI, CDZIP) ("Cadiz" or the "Company") today announced that it has entered into a placement agent agreement for the purchase and ...[8:17:00 AM ET]RXT$2.91+0.02(+0.69%)HGS Selects Rackspace Technology for Private AI Infrastructure Powered by AMD[8:15:00 AM ET]CACI$670.60+4.34(+0.65%)CACI Awarded $185 Million U.S. Army Task Order to Advance Expeditionary Power and Mission Readiness CACI International Inc (NYSE: CACI) announced today that it has been awarded a five-year task order valued at up to $185 million to support the U.S....[8:15:00 AM ET]SILC$41.00-3.16(-7.16%)Silicom Reports Q3 2026 Results Silicom Ltd. (NASDAQ: SILC), an industry-leading provider of high-performance server/appliance networking solutions, today reported its financial...[8:15:00 AM ET]BORR$4.39-0.00(-0.02%)Borr Drilling Limited - Prospector 5 Rig Incident Update - October 29, 2026 Borr Drilling Limited (NYSE and OSE: BORR) ("Borr Drilling" or the "Company") provides an update on the Prospector 5 incident offshore Gabon, first...[8:14:00 AM ET]DAIC$1.01-0.05(-4.72%)Dot Ai Receives Favorable Decision from Nasdaq Hearing Panel[8:13:00 AM ET]HLSQ$0.18+0.01(+4.01%)Zorronet Secures Additional Order from Major Israeli Defense Organization to Extend Range of Autonomous Systems Tessera Defense and Homeland Security Inc. (NYSE American: HLSQ) ("Tessera" or the "Company"), today announced that its subsidiary, Zorronet Ltd....[8:10:00 AM ET]FMCC$3.64-0.27(-6.91%)Freddie Mac Announces Third Quarter 2026 Financial Results[8:09:08 AM ET]SCIA$10.51-0.27(-2.50%)SCI Engineered Materials, Inc. Reports 2026 Third Quarter and Year-to-Date Results[8:07:00 AM ET]MNST$46.46+0.80(+1.75%)Monster Beverage to Report Financial Results for 2026 Third Quarter on November 5, 2026[8:05:00 AM ET]RIGL$51.25+0.51(+1.01%)Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2026 financial results after market close on...[8:05:00 AM ET]CARE$30.29+0.07(+0.23%)Carter Bankshares, Inc. Declares Quarterly Dividend[8:05:00 AM ET]FLNT$3.01+0.25(+9.20%)Fluent, Inc. to Announce 2026 Third Quarter Financial Results and Host Earnings Conference Call on November 12, 2026[8:03:00 AM ET]

PYPD · NASDAQ

PolyPid Ltd.

$5.85 +0.10 (+1.74%)

Company overview

PolyPid Ltd. is a late-stage biopharma company that develops, manufactures, and commercializes products based on its polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trials for the prevention of sternal (bone) surgical site infections (SSIs) as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$119M
Employees
57
Headquarters
Petah Tikva
Website
polypid.com
CEO
Dikla Czaczkes Akselbrad
Listed
June 26, 2020
P/E
-3.06
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$16.1M
EBITDA
-$32.7M
Net income
-$33.6M
EPS
-$1.91
Total assets
$19.2M
Total debt
$2.3M
Earnings yield
-32.65%

Price chart

3.564.144.725.305.88
PYPD 1D NASDAQ O5.77H5.78L5.54C5.75-0.02 (-0.35%)Vol36.93K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
PYPDPolyPid Ltd. Press release PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026 GlobeNewswire
PYPDPolyPid Ltd. Stock news PolyPid Targets 2027 D-PLEX100 Launch, Unveils Diabetic Foot Infection Program MarketBeat
PYPDPolyPid Ltd. Press release PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections GlobeNewsWire
PYPDPolyPid Ltd. Press release PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026 GlobeNewswire
PYPDPolyPid Ltd. Press release PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026 GlobeNewswire
PYPDPolyPid Ltd. Stock news PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data Defense World
PYPDPolyPid Ltd. Stock news PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data MarketBeat
PYPDPolyPid Ltd. Press release European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX₁₀₀ GlobeNewsWire
PYPDPolyPid Ltd. Press release PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities GlobeNewsWire
PYPDPolyPid Ltd. Stock news PolyPid Announces Participation in Upcoming Fall Investor Conferences GlobeNewsWire
PYPDPolyPid Ltd. Stock news PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript Seeking Alpha
PYPDPolyPid Ltd. Stock news PolyPid Q2 Earnings Call Highlights MarketBeat
PYPDPolyPid Ltd. Press release PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results GlobeNewsWire
PYPDPolyPid Ltd. Stock news PolyPid, Azurity sign surgical site infection drug deal Reuters
PYPDPolyPid Ltd. Press release PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada Globe News Wire
PYPDPolyPid Ltd. Press release PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada GlobeNewsWire
PYPDPolyPid Ltd. Press release PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀ GlobeNewsWire
PYPDPolyPid Ltd. Press release PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference GlobeNewsWire
PYPDPolyPid Ltd. Stock news PolyPid Q1 Earnings Call Highlights MarketBeat
PYPDPolyPid Ltd. Stock news PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript Seeking Alpha
See more
FAQ

Questions about PolyPid Ltd.

What does PolyPid Ltd. do?
PolyPid Ltd. is a late-stage biopharma company that develops, manufactures, and commercializes products based on its polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trials for the prevention of sternal (bone) surgical site infections (SSIs) as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
What is PYPD's market cap?
PolyPid Ltd. (PYPD) is a listed stock with a live quote. The latest market cap on this page is $119M.
Where is PolyPid Ltd. headquartered?
PolyPid Ltd. is headquartered in Petah Tikva.
How do I get PYPD news from the API?
Call GET /v1/news?tickers=PYPD. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does PYPD news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PYPD, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the PYPD price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs